Get the Stockscreener App
13.67
4.11%
0.54
Quidelortho Corp stock is traded at $13.67, with a volume of 2.15M.
It is up +4.11% in the last 24 hours and up +26.11% over the past month.
QuidelOrtho Corp is engaged in the development, manufacturing, and marketing of rapid diagnostic testing solutions. The company is engaged in immunoassay and molecular testing, clinical chemistry, and transfusion medicine, which helps clinicians and patients to make decisions across the globe. Geographically, the company has its presence in North America, EMEA, China, and Other countries. It generates the majority of its revenue from North America.
See More
Previous Close:
$13.13
Open:
$13.33
24h Volume:
2.15M
Relative Volume:
0.93
Market Cap:
$932.17M
Revenue:
$2.66B
Net Income/Loss:
$-1.21B
P/E Ratio:
-0.7671
EPS:
-17.82
Net Cash Flow:
$-159.40M
1W Performance:
-2.98%
1M Performance:
+26.11%
6M Performance:
-51.73%
1Y Performance:
-51.75%
1-Day Range:
$13.12
$13.73
1-Week Range:
$13.01
$14.99
52-Week Range:
$9.92
$35.58
Quidelortho Corp Stock (QDEL) Company Profile
Name
Quidelortho Corp
Sector
Industry
Phone
(858) 552-1100
Address
9975 SUMMERS RIDGE ROAD, SAN DIEGO, CA
Compare QDEL vs ABT, SYK, MDT, BSX, EW
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
QDEL
Quidelortho Corp
|
13.67 | 932.17M | 2.66B | -1.21B | -159.40M | -17.82 |
ABT
Abbott Laboratories
|
88.41 | 153.99B | 45.13B | 6.28B | 7.38B | 3.5895 |
SYK
Stryker Corp
|
307.80 | 118.00B | 25.27B | 3.34B | 4.57B | 8.6334 |
MDT
Medtronic Plc
|
79.34 | 101.86B | 36.36B | 4.84B | 5.43B | 3.7212 |
BSX
Boston Scientific Corp
|
45.29 | 67.32B | 20.62B | 3.56B | 3.48B | 2.3847 |
EW
Edwards Lifesciences Corp
|
87.36 | 50.30B | 6.30B | 1.07B | 1.09B | 1.8406 |
Quidelortho Corp Stock (QDEL) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Oct-07-25 | Downgrade | Citigroup | Buy → Neutral |
| May-08-25 | Upgrade | Jefferies | Hold → Buy |
| Dec-11-24 | Upgrade | Citigroup | Neutral → Buy |
| Dec-10-24 | Initiated | Jefferies | Hold |
| Sep-19-24 | Resumed | UBS | Neutral |
| Sep-05-24 | Upgrade | Craig Hallum | Hold → Buy |
| Mar-04-24 | Downgrade | UBS | Neutral → Sell |
| Feb-14-24 | Downgrade | JP Morgan | Neutral → Underweight |
| Dec-11-23 | Downgrade | Citigroup | Buy → Neutral |
| Dec-12-22 | Upgrade | Citigroup | Neutral → Buy |
| Dec-07-22 | Initiated | RBC Capital Mkts | Outperform |
| Oct-14-22 | Upgrade | UBS | Sell → Neutral |
| Sep-19-22 | Initiated | Citigroup | Neutral |
| Jul-20-22 | Initiated | UBS | Sell |
| Jun-17-22 | Resumed | JP Morgan | Neutral |
| Feb-22-22 | Upgrade | Raymond James | Outperform → Strong Buy |
| Jan-22-21 | Upgrade | Raymond James | Mkt Perform → Outperform |
| May-12-20 | Downgrade | JP Morgan | Neutral → Underweight |
| Mar-26-20 | Downgrade | Barclays | Overweight → Equal Weight |
| Oct-23-18 | Resumed | Raymond James | Strong Buy |
| Mar-08-18 | Upgrade | Raymond James | Outperform → Strong Buy |
| Jan-22-18 | Reiterated | Barclays | Overweight |
| Jan-04-18 | Upgrade | CL King | Neutral → Buy |
| Sep-19-17 | Upgrade | Piper Jaffray | Neutral → Overweight |
| Jul-18-17 | Upgrade | Canaccord Genuity | Hold → Buy |
| Jul-18-17 | Upgrade | William Blair | Mkt Perform → Outperform |
| Apr-25-17 | Reiterated | Canaccord Genuity | Hold |
| Feb-17-17 | Initiated | CL King | Neutral |
| Dec-16-16 | Downgrade | Piper Jaffray | Overweight → Neutral |
| Jun-13-16 | Upgrade | Raymond James | Mkt Perform → Outperform |
| Feb-18-16 | Reiterated | Barclays | Overweight |
| Feb-09-16 | Downgrade | Canaccord Genuity | Buy → Hold |
| Jan-08-16 | Reiterated | Canaccord Genuity | Buy |
| Dec-14-15 | Downgrade | Raymond James | Outperform → Mkt Perform |
| Sep-02-15 | Initiated | Barclays | Overweight |
| Jul-31-13 | Reiterated | Canaccord Genuity | Buy |
| Mar-03-11 | Downgrade | Wedbush | Outperform → Neutral |
View All
Quidelortho Corp Stock (QDEL) Latest News
QuidelOrtho Corp (QDEL) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
QuidelOrtho Corp (QDEL) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
QuidelOrtho Corp (QDEL) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
QuidelOrtho Corp (QDEL) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
QuidelOrtho Corp (QDEL) Valuation: PE, PB & Fair Value Analysis - TradingKey
Reasons to retain QuidelOrtho stock in your portfolio for now - MSN
Reasons to Retain QuidelOrtho Stock in Your Portfolio for Now - Yahoo Finance
QuidelOrtho Corp (QDEL) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
QuidelOrtho Corp (QDEL) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Is QuidelOrtho Corp (QDEL) a Bargain After 3.3% Drop? GF Value S - GuruFocus
QuidelOrtho (QDEL) shareholders approve board slate, say-on-pay and KPMG - Stock Titan
QuidelOrtho Corp Annual Shareholders Meeting Transcript - GuruFocus
QuidelOrtho and Allo Hope Foundation partner to advance prenatal care for maternal alloimmunization - Select Science
Is the options market predicting a spike in QuidelOrtho stock? - MSN
QuidelOrtho (QDEL) up 24.1% since last earnings report: Can it continue? - MSN
Is the Options Market Predicting a Spike in QuidelOrtho Stock? - TradingView
QuidelOrtho (QDEL) director receives 1,183 shares from restricted stock unit release - Stock Titan
QuidelOrtho (QDEL) director settles 973 RSUs into common stock award - Stock Titan
QuidelOrtho (NASDAQ: QDEL) director gains 2,156 shares via RSU release - Stock Titan
QuidelOrtho Corp (QDEL) director gains 1,252 shares from RSU release - Stock Titan
QuidelOrtho CorporationCommon Stock (NQ: QDEL - FinancialContent
A Look At QuidelOrtho (QDEL) Valuation After Recent Share Price Rebound And Longer Term Weakness - Yahoo Finance
Assessing QuidelOrtho (QDEL) Valuation After A Sharp One Month Share Price Rebound - simplywall.st
QuidelOrtho (QDEL) Up 24.1% Since Last Earnings Report: Can It Continue? - Yahoo Finance
QuidelOrtho's Respiratory Exposure Remains a Key Near-Term Risk - TradingView
QuidelOrtho Corporation (QDEL) Presents at 46th Annual William Blair Growth Stock ConferenceSlideshow - Seeking Alpha
QuidelOrtho Corp stock (US7476011036): partnership news and conference appearance in focus - AD HOC NEWS
QuidelOrtho (QDEL) director adds 6,829 shares via RSU vesting - Stock Titan
Director at QuidelOrtho (QDEL) gains 6,829 shares through RSU vesting - Stock Titan
QuidelOrtho (QDEL) director RSUs vest into 6,829 shares, holding 19,469 directly - Stock Titan
QuidelOrtho (QDEL) director adds 6,829 shares through RSU vesting - Stock Titan
QuidelOrtho (QDEL) director gains 6,829 shares as RSUs vest - Stock Titan
Director R. Scott Huennekens gains 6,829 QuidelOrtho (QDEL) shares via RSU vesting - Stock Titan
QuidelOrtho Corp (QDEL) director awarded 6,829 shares in equity grant - Stock Titan
QuidelOrtho (QDEL) director Ann D. Rhoads receives 6,829 shares as RSUs vest - Stock Titan
Director at QuidelOrtho (QDEL) gains 6,829 shares via RSU vesting - Stock Titan
QuidelOrtho (QDEL) director awarded 6,829 shares via RSU vesting - Stock Titan
QuidelOrtho and Allo Hope Foundation Join Forces to Advance Educ - GuruFocus
QuidelOrtho Partners with Allo Hope Foundation for Early Pregnan - GuruFocus
QuidelOrtho and Allo Hope Foundation Join Forces to Advance Education, Connection and Early Testing for Alloimmunized Pregnancies - Barchart
McIntyre Partnerships’ Analysis on QuidelOrtho Corporation (QDEL) - Insider Monkey
QuidelOrtho Corp stock (US7476011036): shares volatile after Q1 2026 loss and outlook reset - AD HOC NEWS
QuidelOrtho (QDEL) reports Q1 loss, tops revenue estimates - MSN
QuidelOrtho Corp stock (US7476011036): director share purchase and CFO transition in focus - AD HOC NEWS
A Look at QuidelOrtho Corp (QDEL) After 6.0% Gain -- GF Value $3 - GuruFocus
Director at QuidelOrtho (QDEL) receives 1,407 shares from RSU release - Stock Titan
QuidelOrtho Q1 2026 Earnings: EPS Misses Estimates Sharply, Stock Declines 4.28%Fiscal Year Earnings - thelegaladvocate.com
QuidelOrtho Corp (QDEL) Stock Down 4.2% -- Now Undervalued? GF S - GuruFocus
How Quidelortho Corp Com (QDEL) Affects Rotational Strategy Timing - Stock Traders Daily
When Blood Compatibility Becomes a Pregnancy Risk – Company Announcement - Financial Times
QuidelOrtho stock (US7476011036): Shares rise after latest market move - AD HOC NEWS
Quidelortho Corp Stock (QDEL) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.93%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):